Patients with histologically confirmed stage IV NSCLC were randomized @ : @ to receive gemcitabine ( @ mg/m ( @ ) , days @/@ ) and cisplatin ( @ mg/m ( @ ) , day @ ) with -LSB- gemcitabine/cisplatin/iniparib ( GCI ) -RSB- or without -LSB- gemcitabine/cisplatin ( GC ) -RSB- iniparib ( @ mg/kg , days @/@/@ / @ ) every @ weeks for six cycles .